Skip to content

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

Study finds antiretroviral therapy cost-effective in South African setting

Clinical and immunological benefits lasting at least three years reported by large Kenyan antiretroviral programme

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

ICAAC: Women who shed HSV in genitals shed more HIV

ICAAC: HCV only factor associated with liver problems in patients starting HIV treatment in 2004

ICAAC: Dividing Triomune tablets may result in inadequate doses for small children; liquid best

ICAAC: TMC114 shows further promise in second POWER study

Ugandan ART programme claims to reduce sexual risk taking and the risk of HIV transmission